---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-247410"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:30:32.401308+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics priced 11.4M-share offering at $22/sh for ~$251M gross proceeds

## Summary
- Offering of 11,425,000 shares at $22.00/share; underwriters have 30-day option for up to 1,713,750 additional shares.
- Gross proceeds of ~$251.35M before underwriting discounts and expenses; closing expected October 23, 2025.
- Net proceeds combined with existing cash, $70M Kissei upfront (Q4 2025), $55M DRI payment, $115M potential DRI milestones, and $30M term loan to fund operations.
- Company assumes revenue from veligrotug and VRDN-003 if approved on anticipated timelines to extend cash runway.

## SEC filing metadata
- accession: 0001193125-25-247410
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525247410/0001193125-25-247410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525247410/d27166d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-247410
- JSON: https://secwatch.observer/filing/0001193125-25-247410.json
- Plain text: https://secwatch.observer/filing/0001193125-25-247410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.